Colin Bristow

Stock Analyst at UBS

(1.91)
# 3,226
Out of 5,044 analysts
103
Total ratings
36.67%
Success rate
-6.43%
Average return

Stocks Rated by Colin Bristow

Gilead Sciences
Aug 8, 2025
Maintains: Neutral
Price Target: $108$112
Current: $117.88
Upside: -4.99%
Vertex Pharmaceuticals
Aug 5, 2025
Maintains: Buy
Price Target: $582$553
Current: $422.39
Upside: +30.92%
PTC Therapeutics
Jul 29, 2025
Maintains: Buy
Price Target: $71$80
Current: $67.49
Upside: +18.54%
Rocket Pharmaceuticals
Jun 17, 2025
Maintains: Buy
Price Target: $12$5
Current: $3.97
Upside: +25.94%
ALX Oncology Holdings
May 21, 2025
Maintains: Buy
Price Target: $1.2$1
Current: $1.54
Upside: -35.06%
Immunovant
Apr 22, 2025
Downgrades: Neutral
Price Target: $38$17
Current: $21.98
Upside: -22.66%
Amgen
Apr 14, 2025
Maintains: Neutral
Price Target: $315$319
Current: $292.09
Upside: +9.21%
Acumen Pharmaceuticals
Mar 28, 2025
Maintains: Buy
Price Target: $6$4
Current: $2.29
Upside: +74.67%
enGene Holdings
Feb 14, 2025
Downgrades: Neutral
Price Target: $34$7
Current: $7.81
Upside: -10.37%
Pfizer
Feb 5, 2025
Maintains: Neutral
Price Target: $29$28
Current: $24.50
Upside: +14.29%
Maintains: Buy
Price Target: $125$120
Current: $87.03
Upside: +37.88%
Maintains: Neutral
Price Target: $234$202
Current: $149.13
Upside: +35.45%
Maintains: Neutral
Price Target: $56$16
Current: $2.18
Upside: +633.94%
Maintains: Buy
Price Target: $1,090$1,099
Current: $654.48
Upside: +67.92%
Maintains: Buy
Price Target: $164$167
Current: $24.22
Upside: +589.51%
Maintains: Buy
Price Target: $428$420
Current: $820.10
Upside: -48.79%
Downgrades: Neutral
Price Target: $12$2
Current: $7.96
Upside: -74.87%
Initiates: Buy
Price Target: $18
Current: $3.04
Upside: +492.11%
Maintains: Neutral
Price Target: $154$146
Current: $227.54
Upside: -35.84%
Maintains: Neutral
Price Target: $73$75
Current: $42.82
Upside: +75.15%
Maintains: Buy
Price Target: $64$26
Current: $2.58
Upside: +907.75%
Initiates: Buy
Price Target: $9
Current: $5.60
Upside: +60.71%